Median absolute B-cell count at diagnosis
| Prognostic factors/variable . | No. of patients . | Median B-cell count, ×109/L (1st, 3rd quartile) . | Difference in median B-cell count, P . |
|---|---|---|---|
| All patients | 459 | 5.9 (3.7, 11.2) | |
| Sex | .25 | ||
| Male | 278 | 5.8 (3.8, 11.8) | |
| Female | 181 | 5.9 (3.5, 10.4) | |
| CD38 | .76 | ||
| Positive, ≥ 30% | 83 | 6.0 (3.7, 11.2) | |
| Negative, < 30% | 355 | 5.9 (3.7, 11.2) | |
| ZAP-70 | .60 | ||
| Positive, ≥ 20% | 63 | 6.9 (4.2, 10.9) | |
| Negative, < 20% | 215 | 5.8 (3.8, 10.9) | |
| IGHV gene mutation status | .003 | ||
| Unmutated | 87 | 8.7 (4.4, 13.8) | |
| Mutated | 190 | 5.4 (3.7, 10.4) | |
| FISH result | .05 | ||
| 13q− | 149 | 6.5 (4.1, 11.9) | |
| Normal | 81 | 6.3 (3.7, 10.3) | |
| +12 | 42 | 5.5 (3.3, 9.7) | |
| 11q− | 16 | 11.6 (5.7, 19.2) | |
| 17p− | 11 | 4.5 (3.2, 12.7) |
| Prognostic factors/variable . | No. of patients . | Median B-cell count, ×109/L (1st, 3rd quartile) . | Difference in median B-cell count, P . |
|---|---|---|---|
| All patients | 459 | 5.9 (3.7, 11.2) | |
| Sex | .25 | ||
| Male | 278 | 5.8 (3.8, 11.8) | |
| Female | 181 | 5.9 (3.5, 10.4) | |
| CD38 | .76 | ||
| Positive, ≥ 30% | 83 | 6.0 (3.7, 11.2) | |
| Negative, < 30% | 355 | 5.9 (3.7, 11.2) | |
| ZAP-70 | .60 | ||
| Positive, ≥ 20% | 63 | 6.9 (4.2, 10.9) | |
| Negative, < 20% | 215 | 5.8 (3.8, 10.9) | |
| IGHV gene mutation status | .003 | ||
| Unmutated | 87 | 8.7 (4.4, 13.8) | |
| Mutated | 190 | 5.4 (3.7, 10.4) | |
| FISH result | .05 | ||
| 13q− | 149 | 6.5 (4.1, 11.9) | |
| Normal | 81 | 6.3 (3.7, 10.3) | |
| +12 | 42 | 5.5 (3.3, 9.7) | |
| 11q− | 16 | 11.6 (5.7, 19.2) | |
| 17p− | 11 | 4.5 (3.2, 12.7) |